A systematic review of the fetal safety of interferon alpha

StephenW

Reprod Toxicol. 2011 Dec 19.Source:
http://www.ncbi.nlm.nih.gov/pubmed/22200624 A systematic review of the
fetal safety of interferon alpha. Yazdani Brojeni P, Matok I, Garcia
Bournissen F, Koren G. The Motherisk Program, Hospital for Sick Children,
University of Toronto, Canada.

Abstract
BACKGROUND:
Interferon alpha (IFN) is an effective treatment for a variety of
conditions including essential thrombocythemia (ET), chronic myelocytic
leukemia, Hepatitis B and C. Because these conditions also occur in women
of childbearing age who may become pregnant, information regarding the
safety of this medication in pregnancy is essential. This systematic review
attempts to summarize all published data on outcome of pregnancies exposed
to IFN alpha, trying to differentiate between disease effect and drug
effect.

METHODS:
Reports on the use of IFN alpha in human pregnancy and reports on essential
thrombocythemia (ET) without use of any medication in pregnancy were
identified by a systematic search of the medical literature. We were able
to locate only case reports of IFN alpha exposure in pregnancy, of whom 40
out of 63 were diagnosed with ET. We also collected randomly 71 cases (more
cases were available in the literature) that were diagnosed with ET due to
different etiologies, but who had not received any medication in
pregnancy.

RESULTS:
Among the 63 IFN alpha exposures in pregnancy, the mean maternal age was
30±6 years and the mean full term babies' weight was 3096±463g. Mean
gestational age at delivery was 37±3 weeks. There were 55 single and 4
twin pregnancies. No cases of major malformations or stillbirths were
reported. There was one case of spontaneous abortion and 13 preterm
deliveries (20% of all exposed cases). Among the 71 cases with untreated ET
in pregnancy of different etiologies, 46 (65%) had early (within the first
12 weeks of pregnancy) or late (13-20 weeks of gestation) pregnancy loss.
There were also 3 cases (4%) of stillbirth and 4 cases (5.6%) of preterm
delivery. Only 18 women (25%) delivered healthy term babies.

CONCLUSIONS:
The results of our systematic review suggest that IFN-alpha does not
significantly increase the risk of major malformation, miscarriage,
stillbirth or preterm delivery above general population rates. It is also
possible that IFN-alpha may have a protective effect against pregnancy loss in
cases of ET.

StephenW

Reprod毒性。 2011月19.Source：
http://www.ncbi.nlm.nih.gov/pubmed/22200624一个系统的审查
干扰素α胎儿安全。 Yazdani Brojeni P，我Matok，加西亚
Bournissen楼科任G. Motherisk计划，儿童医院，
加拿大多伦多大学。

摘要
背景：
干扰素α（IFN）是一种有效的治疗各种
包括原发性血小板增多症（ET），慢性粒​​细胞的条件
白血病，乙肝和丙肝因为这些条件也发生在女性
育龄妇女可能怀孕，有关的信息
在孕期用药的安全是至关重要的。该系统评价
试图总结所有公布的数据显示，暴露怀孕的结果
干扰素α，试图区分疾病和药物效果
效果。

方法：
在人类怀孕和必要的报告，使用干扰素α的报告
没有使用任何药物，在怀孕期间血小板增多症（ET）的;
鉴定的医学文献的系统性检索。我们能够
定位在怀孕干扰素α曝光的唯一病例报告，其中40
被诊断出63与ET。我们也随机收集71例（
宗文献中可用），诊断与ET由于
不同的病因，但谁没有收到任何药物
怀孕。

结果：
其中63干扰素阿尔法暴露在怀孕期间，产妇平均年龄
30 ± 6年，平均全足月婴儿的体重为3096 ±463克。平均
分娩时的孕周是37 ± 3个星期。有55单和4
双胎妊娠。主要畸形或死胎病例
报告。之一的情况下自然流产和13早产
交付（20％的情况下所有外露）。在与未经处理的ET的71例
在不同的病因，46（65％）怀孕早期（在第一
妊娠12周）或晚期（13-20孕周）妊娠丢失。
也有3例（4％），早产，死产和4例（5.6％）
交货。只有18名妇女（25％）提供了健康的足月婴儿。

结论：
我们系统的审查结果表明，IFN -α不
显著增加的风险主要畸形，流产，
死胎或早产以上总人口率。这也是
可能，IFN -α可能有一个对流产的保护作用
例ET的。

kujinganla

额的神啊，google翻译就搬出来了